ALKS
Alkermes plc · Healthcare · Drug Manufacturers - Specialty & Generic
Momentum inputs (comparable managers):
holder breadth +11.8% ·
share flow -3.1% ·
net new positions +10.5%
· formula
Ownership fragmentation: more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 8.96K | $359,305 | n/a | n/a |
| Q2 2026 | 121 | +1 | 123.14M | $6.45B | +12 | −10 |
| Q1 2026 | 122 | -3 | 122.08M | $4.29B | +3 | −7 |
| Q4 2025 | 124 | +2 | 142.93M | $4.00B | +3 | n/a |
| Q3 2025 | 20 | -1 | 95.12M | $2.85B | n/a | −2 |
| Q2 2025 | 19 | +2 | 84.64M | $2.42B | +2 | n/a |
| Q1 2025 | 14 | 0 | 39.73M | $1.31B | n/a | n/a |
| Q4 2024 | 14 | 0 | 45.20M | $1.30B | n/a | n/a |
| Q3 2024 | 13 | +2 | 43.42M | $1.22B | +2 | n/a |
| Q2 2024 | 11 | n/a | 42.07M | $1.01B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 27.86M | n/a | $796.96M | 0.0% | n/c | 1 | SEC ↗ ×21 |
| 2 | The Vanguard Group ✦ (passive) | 18.50M | n/a | $529.37M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 3 | T. Rowe Price ✦ | 10.04M | -14.8% | $287.30M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 4 | State Street Global Advisors ✦ (passive) | 8.21M | +2.3% | $234.84M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 5 | Renaissance Technologies ✦ | 5.81M | +1.2% | $166.23M | 0.2% | ▲ Add | 5 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 4.02M | +2.1% | $115.13M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 7 | PRIMECAP Management ✦ | 2.90M | -3.4% | $83.04M | 0.1% | ▼ Trim | 5 | SEC ↗ |
| 8 | Norges Bank ✦ (passive) | 1.86M | -2.8% | $53.33M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 9 | Wellington Management ✦ | 1.70M | -45.1% | $48.64M | 0.0% | ▼ Trim | 5 | SEC ↗ ×5 |
| 10 | Fidelity (FMR) ✦ | 1.28M | n/a | $36.56M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 11 | D. E. Shaw & Co. ✦ | 820.10K | +75.0% | $23.46M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 12 | AQR Capital Management ✦ | 452.52K | -15.0% | $12.95M | 0.0% | ▼ Trim | 5 | SEC ↗ ×4 |
| 13 | Two Sigma Investments ✦ | 325.90K | -41.6% | $9.32M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 14 | Fisher Asset Management ✦ | 291.95K | -9.2% | $8.35M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 15 | Marshall Wace ✦ | 207.51K | New | $5.94M | 0.0% | New | 1 | SEC ↗ ×2 |
| 16 | Gotham Asset Management ✦ | 133.47K | +67.5% | $3.82M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 17 | Arrowstreet Capital ✦ | 103.28K | New | $2.95M | 0.0% | New | 1 | SEC ↗ |
| 18 | Millennium Management ✦ | 77.94K | -56.0% | $2.23M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 19 | Citadel Advisors ✦ | 37.42K | -55.6% | $1.07M | 0.0% | ▼ Trim | 5 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $5.94M | 0.0% |
| Arrowstreet Capital | $2.95M | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 384 holders, 171.47M shares, $5.79B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 2.03K sh · $83,455
Officer · 2.03K sh · $97,652
Officer · 9.00K sh · $422,874
Officer · 6.91K sh · $339,967
Officer · 664 sh · $32,969
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology